Effect and Safety of dose-escalating treatment of Imidafenacin for Overactive Bladder : CLSS-modified-Self-Assessment Goal Achievement questionnaire

Effect and Safety of dose-escalating treatment of Imidafenacin for Overactive Bladder : CLSS-modified-Self-Assessment Goal Achievement questionnaire - CLSS-modified-SAGE study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004894

Enrollment

500

Registered

2011-01-18

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Interventions

imidafenacin 0.2mg/day-0.4mg/day bid.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Man and Woman over 20years who had OAB symptom, >=8voids/day, urgency and would like to have a treatment for OAB symptom.

Exclusion criteria

Exclusion criteria: 1)Polyuria (daily urine volume >=3000mL) 2)Residual urine >=100mL 3)Suspect of prostate cancer 4)Indwelling catheter or self intermittent urinary catherization 5)The shift work and patients with irregular lifestyle 6)Bladder training conducted over the past 10 days 7)Active urinary tract infection 8)Having been given hormones or 5 alpha-reductase inhibitor within the past six months 9)Contraindication to imidafenacin (Primary angle-closure glaucoma , urinary retention , Obstructive intestinal disease, paralytic ileus, gastrointerstinal atony , myastania gravis ) 10)Judged as being unsuitable for the trial by the researcher.

Design outcomes

Primary

Measure	Time frame
1)CLSS-modified-Self-Assessment Goal Achievement questionnaire : CLSS-modified-SAGA 2)Overactive Bladder Symptom Score : OABSS	—

Secondary

Measure	Time frame
1) IPSS-QOL 2) residual urine volume 3) adverse events and side-effects	—

Countries

Japan

Contacts

Public ContactAkihiro Yanagiuchi

Kobe University Graduate School of Medicine urology

urokobe@med.kobe-u.ac.jp078-382-6155

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026